Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02202772 · ClinicalTrials.gov registry record · Phase 1
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder
A Phase 1 study of Urothelial Carcinoma of the Urinary Bladder, sponsored by Guarionex J. Decastro.
- Active
- Registry status
- Phase 1
- Development phase
- 51
- Enrollment target
- 1
- Study location
NCT02202772: Active Phase 1 study of Urothelial Carcinoma of the Urinary Bladder, sponsored by Guarionex J. Decastro.
NCT02202772 is a Phase 1 study of Urothelial Carcinoma of the Urinary Bladder that is active but no longer recruiting, run by Guarionex J. Decastro. The registered enrollment target is 51 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02202772, a Phase 1 study of Urothelial Carcinoma of the Urinary Bladder, is active but no longer recruiting, sponsored by Guarionex J. Decastro.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 51 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators intend to evaluate the safety and toxicity profile of intravesically administered multidrug regimen of Cabazitaxel, Cisplatin and Gemcitabine in treatment refractory Transitional Cell Carcinoma.The investigators propose to conduct a combined phase I trial to assess the safety, toxicity, and efficacy of a novel multidrug intravesical regimen consisting of Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of BCG resistant non-muscle invasive urothelial carcinoma of the bladder. This phase I trial will have a combined dose and cycle-escalation scheme with enrollment of up to 24 patients.
Primary Outcome
The investigator is measuring safety by looking at the number of events that occur during the study
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DRUG Cabazitaxel
Study Locations (1)
New York
- Columbia University Irving Medical Center - HIP - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2014-12-01 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
What the registry record for NCT02202772 still lists
NCT02202772 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Urothelial Carcinoma of the Urinary Bladder appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT02202772 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02202772 about?
NCT02202772 is a clinical study titled "Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder". The investigators intend to evaluate the safety and toxicity profile of intravesically administered multidrug regimen of Cabazitaxel, Cisplatin and Gemcitabine in treatment refractory Transitional Cell Carcinoma.The investigators propose to conduct a combined phase I trial to assess the safety, toxic...
What is the current status of trial NCT02202772?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 51 participants. The study started on 2014-12-01. Estimated completion is 2028-04.
What conditions does trial NCT02202772 study?
This clinical trial studies the following conditions: Urothelial Carcinoma of the Urinary Bladder.
What interventions are being tested in trial NCT02202772?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), Cabazitaxel (DRUG).
Who is sponsoring clinical trial NCT02202772?
This trial is sponsored by Guarionex J. Decastro, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02202772 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02202772's enrollment target sits among peer trials
51 969th of 2000 higher than 1,028 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI